Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH [68]. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.